The development of the retinal vascular network is completed during the third trimester of pregnancy and and the first 15 days of life of the newborn. This late maturation can be problematic in cases of preterm births and result in immature retinal vascularization, known as retinopathy of prematurity (ROP). Among the various factors influencing retinal vascular development, the tissue content of omega-3 polyunsaturated fatty acids (PUFAs) appears to be a crucial element. In a previous project, OMEGA-ROP, we showed a difference in the blood bioavailability of omega-3 PUFAs in infants born at less than 28 weeks of amenorrhea who develop ROP compared to healthy newborns with no retinopathy. This study also showed that mothers experienced variations in the blood levels of omega-3 PUFAs that were contrary to the types of variations observed in their children. This suggests a sequestration of omega-3 PUFAs in the mothers of children who will develop ROP. This new project aims to better understand the underlying molecular mechanisms by studying the expression levels of placental fatty acid receptors in relation to the development of ROP in newborns.
Mothers giving birth to premature babies less than 29 weeks of amenorrhea (WA), after obtaining their non-opposition.
Mothers giving birth at term between 39 and 41WA+6 days, after obtaining their non-opposition.
≥18 years
Mothers not under legal protection
Mothers giving birth between 29WA and 38WA+6 days
Mothers in critical condition.
Person not affiliated to national health insurance
For full-term mothers: patient presenting or having presented a health condition that affected a previous pregnancy (vascular such as pregnant hypertension, preeclampsia; gestational diabetes; intrauterine growth retardation, maternal infection during pregnancy such as toxoplasmosis, cytomegalovirus, rubella, measles, chickenpox).
Women giving birth at term or prematurely
Case-control
Prospective
Maternal blood sampling
Biological/Vaccine5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
Umbilical cord blood sampling
Biological/Vaccine0.5mL sample from the umbilical cord after childbirth standard protocols
Placenta sampling
Biological/VaccineSampling of 3 cotyledons by cutting across the thickness of the placenta
Data collection
Other interventionNewborn, Maternal and Premature Retinopathy Screening Data Collection
Estimation of the linear correlation coefficient between placental fatty acid receptor expression rate and term of delivery
Click on the lead sponsor to view all of their trials.
